10.1042/BST20200270 Summary Keywords GLP-1, immunemetabolic signaling, metabolic disease, neuroendocrine peptides, orphan receptors, peptide therapeutics, polypharmacology Citation Niazi SK (2026) Beyond GLP-1: underexplored peptidereceptor systems as the next frontier in drug discovery
A large proportion of these studies reported on the impact of GLP-1RAs on dopaminergic neurotransmission responsible for reward processingwhich could contribute to their efficacy as anti-obesity medications by means of a reduction of food-related incentive 110
Obesity in teens and adolescents has become a significant problem, with nearly one in five children in the United States now classified as overweight or obese
It is not recommended in patients with severe gastrointestinal disease, including severe gastroparesis
Unlike other weight loss medications that suppress appetite, Alli works directly in your digestive system. Given the way Alli works, it may not be suitable for those who don't match the criteria
Living in an environment that has progressively worsened in the last 50 years has led over 94% of our country to become metabolically dysfunctional
